01273 704473

info@novuscomms.com

01273 704473

info@novuscomms.com

#POLB Poolbeg Pharma PLC – Significant POLB 001 Patent Granted in USA May 1, 2024 – Posted in: Poolbeg Pharma (POLB)

1 May 2024- Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that, further to its announcement on 20 March 2024, the Company has received the fully granted patent from the US Patent Office for its Immunomodulator II patent application.   The claims cover a class of drugs (including POLB 001) for treating hypercytokinaemia (cytokine…

Continue reading

#POLB Poolbeg Pharma PLC – Former Amryt Pharma Leadership Team join Poolbeg November 9, 2023 – Posted in: Blog, Poolbeg Pharma (POLB)

9 November 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, announces the appointment of key former executives of Amryt Pharma plc (‘Amryt’) to its leadership team. These experienced professionals will assume pivotal roles within Poolbeg, further enhancing the Company’s expertise and capabilities. Poolbeg’s Chairman, Cathal Friel, co-founded both Poolbeg and Amryt Pharma plc. Poolbeg intends to follow a similar strategic approach to Amryt…

Continue reading

#VELA Vela Technologies PLC investee co. #KNB Kanabo Group PLC – Treat It Launch: Online Medicinal Cannabis Clinic March 13, 2023 – Posted in: Vela Technologies Plc (VELA)

Kanabo Group plc (LSE: KNB), a patient-focused Healthtech company, has launched Treat It , a new online medicinal cannabis clinic for pain management. The new clinic aims to address the issue of limited access to pain management treatments for the approximately 8 million chronic pain sufferers in the UK. These individuals face difficulties accessing medical treatments due to long waiting times, bureaucracy, and affordability. According to recent data, 24% of chronic pain sufferers in the UK are…

Continue reading

Poolbeg Pharma PLC #POLB – AI programme yields novel RSV drug targets March 28, 2022 – Posted in: Poolbeg Pharma (POLB)

  Poolbeg Pharma PLC #POLB – AI programme yields novel RSV drug targets Artificial intelligence programme yields multiple novel RSV drug targets First time AI has been used to identify disease targets in RSV 8 November 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces that it has made a significant breakthrough in its Artificial Intelligence (‘AI’) Programme with…

Continue reading

#POLB Poolbeg Pharma – Update on POLB 001 Clinical Development November 18, 2021 – Posted in: Blog, Poolbeg Pharma (POLB)

18 November 2021 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’) a clinical stage infectious disease pharmaceutical company with a capital light clinical model, is pleased to provide an update on the clinical development progress of its lead asset, POLB 001, a small molecule immunomodulator for the treatment of severe influenza. The Company intends to commence the Phase Ib human challenge study of POLB 001 in June 2022 which will be a key step in…

Continue reading

Open Orphan (ORPH) sells its remaining shareholding in Integumen plc July 12, 2019 – Posted in: Open Orphan (ORPH)

Open Orphan, a European-focussed, rare and orphan drug consulting services platform, announces that it has now sold its remaining shareholding in Integumen plc following its disposal of 30,071,428 ordinary shares. The total proceeds of the sale are £566,846. This completes the process begun with the divestment of Innovenn UK limited to Integumen plc in November 2016. The disposal allows the Company to focus all its resources on its core strategy of creating a focused orphan drug platform…

Continue reading